Dallas, Texas (PRWEB) October 22, 2013
Read more
ITO transaction activity in the life sciences industry slowed markedly in 2012, falling from 82 deals to 54, due to multiple challenges that included patent losses, middling R&D productivity, and rising consolidation.
Smaller life sciences firms ? those with less than US$.